Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology is viewed positively because the settlement with Nerviano removes a major overhang on onvansertib’s global rights, reduces litigation risk, and strengthens the company’s strategic control over its lead PLK1 inhibitor. The amended 2017 Exclusive License Agreement adds clearer exclusivity, governance, and development terms around the upcoming Phase 3 program, while preserving potential post-termination royalty economics and milestone-related value. With onvansertib advancing in Phase 2 for first-line RAS-mutated metastatic colorectal cancer and showing single-agent activity in hard-to-treat tumors, the stock’s fundamentals are supported by a differentiated asset in a large, underserved oncology market.

Cardiff Oncology is a clinical-stage biotechnology company whose outlook is constrained by the high uncertainty of onvansertib’s path to approval, reflected in only a 25% probability of launch in 1L KRAS/NRAS+ mCRC and a valuation framework that depends heavily on assumptions such as an 11% discount rate and 1% terminal growth. Its negative fundamentals are driven by trial risk, including the possibility of adverse data from the ongoing CRDF-004 study, as well as delays in moving into pivotal studies and the chance that approval is never secured. The company also faces commercial and financial pressure from potentially smaller-than-expected market penetration, competition, legal risks, and near- to medium-term dilution risk, despite an estimated firm value of $820M and 82.7M shares outstanding.